Clinical treatment of cholangiocarcinoma: an updated comprehensive review
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical treatment of cholangiocarcinoma: an updated comprehensive review
Authors
Keywords
-
Journal
Annals of Hepatology
Volume 27, Issue 5, Pages 100737
Publisher
Elsevier BV
Online
2022-07-07
DOI
10.1016/j.aohep.2022.100737
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.
- (2022) Do-Youn Oh et al. JOURNAL OF CLINICAL ONCOLOGY
- Trends in Incidence and Prognostic Factors of Two Subtypes of Primary Liver Cancers: A Surveillance, Epidemiology, and End Results-Based Population Study
- (2022) Jiping Yao et al. Cancer Control
- Impact on follow‐up strategies in patients with primary sclerosing cholangitis
- (2022) Annika Bergquist et al. LIVER INTERNATIONAL
- Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer
- (2022) Rom Leidner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting FGFR inhibition in cholangiocarcinoma
- (2021) Lipika Goyal et al. CANCER TREATMENT REVIEWS
- FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
- (2021) Adrián Vallejo et al. JOURNAL OF HEPATOLOGY
- The role of lymphadenectomy in the surgical treatment of intrahepatic cholangiocarcinoma: A review
- (2021) Carlo Sposito et al. EJSO
- Cholangiocarcinoma
- (2021) Paul J. Brindley et al. Nature Reviews Disease Primers
- Menopausal hormone therapy and risk of biliary tract cancers
- (2021) Sarah S. Jackson et al. HEPATOLOGY
- Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib
- (2021) James Yu et al. OncoTargets and Therapy
- Current and emerging therapies for advanced biliary tract cancers
- (2021) Audrey E Kam et al. Lancet Gastroenterology & Hepatology
- Systemic therapies for intrahepatic cholangiocarcinoma
- (2020) Robin Kate Kelley et al. JOURNAL OF HEPATOLOGY
- Liver resection and transplantation for intrahepatic cholangiocarcinoma
- (2020) Vincenzo Mazzaferro et al. JOURNAL OF HEPATOLOGY
- Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland
- (2020) Nina Barner-Rasmussen et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Prognostic significance of and risk prediction model for lymph node metastasis in resectable intrahepatic cholangiocarcinoma: do all require lymph node dissection?
- (2020) Jonathan G. Navarro et al. HPB
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
- (2020) Sarina A. Piha-Paul et al. INTERNATIONAL JOURNAL OF CANCER
- FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
- (2020) Lipika Goyal et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
- (2020) Richard D. Kim et al. JAMA Oncology
- New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
- (2020) Sara Massironi et al. Cells
- Phase 1, First-in-Human Study of Futibatinib, a Highly Selective, Irreversible FGFR1–4 Inhibitor in Patients with Advanced Solid Tumors
- (2020) R. Bahleda et al. ANNALS OF ONCOLOGY
- Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial
- (2020) Shalini Makawita et al. Future Oncology
- Molecular targets in cholangiocarcinoma
- (2020) Colm J. O’Rourke et al. HEPATOLOGY
- Cholangiocarcinoma 2020: the next horizon in mechanisms and management
- (2020) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
- (2020) Soomin Ahn et al. Scientific Reports
- Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers
- (2020) Oliver Klein et al. JAMA Oncology
- Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
- (2020) Florent Peyraud et al. Cancers
- Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors
- (2020) Hiroshi Sootome et al. CANCER RESEARCH
- Cholangiocarcinoma miscoding in hepatobiliary centres
- (2020) Shaun Selvadurai et al. EJSO
- Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab
- (2020) Atsushi Naganuma et al. INTERNAL MEDICINE
- Latest evidence on immunotherapy for cholangiocarcinoma (Review)
- (2020) Xurui Guo et al. Oncology Letters
- Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma
- (2020) Gehan Botrus et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Management of primary sclerosing cholangitis and its complications: an algorithmic approach
- (2020) Michal Prokopič et al. Hepatology International
- Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells
- (2020) Thanich Sangsuwannukul et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- A Phase Ib Study of NUC ‐1031 in Combination with Cisplatin for the First‐Line Treatment of Patients with Advanced Biliary Tract Cancer ( ABC ‐08)
- (2020) Mairéad G. McNamara et al. ONCOLOGIST
- The Tumor Microenvironment and Immune Milieu of Cholangiocarcinoma
- (2019) Luca Fabris et al. LIVER INTERNATIONAL
- Second‐line chemotherapy in biliary tract cancer: Outcome and prognostic factors
- (2019) Nora Schweitzer et al. LIVER INTERNATIONAL
- Surgery For Cholangiocarcinoma
- (2019) Umberto Cillo et al. LIVER INTERNATIONAL
- Classifications and misclassification in cholangiocarcinoma
- (2019) Vincenzo Cardinale LIVER INTERNATIONAL
- Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
- (2019) Paola Bertuccio et al. JOURNAL OF HEPATOLOGY
- Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study
- (2019) Julien Edeline et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial.
- (2019) Zev A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).
- (2019) Tatsuya Ioka et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
- (2019) Rastilav Bahleda et al. CLINICAL CANCER RESEARCH
- Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.
- (2019) Joon Oh Park et al. JOURNAL OF CLINICAL ONCOLOGY
- ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
- (2019) Angela Lamarca et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of tumor shrinkage pattern by biweekly triplet gemcitabine/cisplatin/s-1 for biliary tract cancers: Implication for neoadjuvant therapy (KHBO1401-1A study).
- (2019) Shogo Kobayashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
- (2019) Rachna T. Shroff et al. JAMA Oncology
- O-005Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial
- (2019) J Harding et al. ANNALS OF ONCOLOGY
- AGA Institute Clinical Practice Update: Surveillance for Hepatobiliary Cancers in Patients with Primary Sclerosing Cholangitis
- (2019) Christopher L. Bowlus et al. Clinical Gastroenterology and Hepatology
- British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis
- (2019) Michael Huw Chapman et al. GUT
- Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis
- (2019) Oliver Clements et al. JOURNAL OF HEPATOLOGY
- Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
- (2019) Roy S Herbst et al. LANCET ONCOLOGY
- Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
- (2019) Maeve A Lowery et al. Lancet Gastroenterology & Hepatology
- Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker
- (2019) Heejung Chae et al. EUROPEAN JOURNAL OF CANCER
- Mismatch Repair Protein Deficiency/Microsatellite Instability Is Rare in Cholangiocarcinomas and Associated With Distinctive Morphologies
- (2019) Jennifer Y Ju et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
- (2019) Raluca Ioana Teleanu et al. Journal of Clinical Medicine
- Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer
- (2018) T. Ebata et al. BRITISH JOURNAL OF SURGERY
- GenomicERBB2/ERBB3mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis
- (2018) Maolan Li et al. GUT
- Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma
- (2018) Chirag Nepal et al. HEPATOLOGY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
- (2018) Hendrik‐Tobias Arkenau et al. ONCOLOGIST
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers
- (2018) David M. Hyman et al. NATURE
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- (2018) Vincenzo Mazzaferro et al. BRITISH JOURNAL OF CANCER
- A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma
- (2018) Weijing Sun et al. CANCER
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- NTRK fusion-positive cancers and TRK inhibitor therapy
- (2018) Emiliano Cocco et al. Nature Reviews Clinical Oncology
- Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial
- (2017) Loic Verlingue et al. EUROPEAN JOURNAL OF CANCER
- Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis
- (2017) Rudi Alberts et al. GUT
- PD-L1 expression in extrahepatic cholangiocarcinoma
- (2017) Dirk Walter et al. HISTOPATHOLOGY
- Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer
- (2017) Haipeng Lei et al. International Journal of Biological Sciences
- Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway.
- (2017) Milind M. Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.
- (2017) Julien Edeline et al. JOURNAL OF CLINICAL ONCOLOGY
- Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma
- (2017) Kai-chao Feng et al. Journal of Hematology & Oncology
- Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi-institution analysis from the U.S. extrahepatic biliary malignancy consortium
- (2017) Bradley A. Krasnick et al. JOURNAL OF SURGICAL ONCOLOGY
- Postoperative Liver Failure Risk Score: Identifying Patients with Resectable Perihilar Cholangiocarcinoma Who Can Benefit from Portal Vein Embolization
- (2017) Pim B. Olthof et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Cholangiocarcinoma — evolving concepts and therapeutic strategies
- (2017) Sumera Rizvi et al. Nature Reviews Clinical Oncology
- Occupational exposure to asbestos and risk of cholangiocarcinoma: a population-based case–control study in four Nordic countries
- (2017) Andrea Farioli et al. OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
- Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach
- (2017) Marco Presta et al. PHARMACOLOGY & THERAPEUTICS
- Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis
- (2017) Michele Ghidini et al. HPB
- High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
- (2017) Christophe Massard et al. Cancer Discovery
- Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
- (2017) Apinya Jusakul et al. Cancer Discovery
- PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
- (2017) Jacqueline Fontugne et al. Oncotarget
- Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare
- (2017) Jessica L. Petrick et al. PLoS One
- Activation of Fas/FasL pathway and the role of c-FLIP in primary culture of human cholangiocarcinoma cells
- (2017) Gianluca Carnevale et al. Scientific Reports
- Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) J. W. Valle et al. ANNALS OF ONCOLOGY
- Role of staging laparoscopy in the stratification of patients with perihilar cholangiocarcinoma
- (2016) N. Bird et al. BRITISH JOURNAL OF SURGERY
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
- (2016) Xiaojun Liu et al. CANCER RESEARCH
- Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment
- (2016) G. Sapisochin et al. HEPATOLOGY
- Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models
- (2016) Alexandre Doussot et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
- (2016) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
- (2016) Lipika Goyal et al. Cancer Discovery
- Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
- (2016) Terence G. Hall et al. PLoS One
- Prognostic factors for progression-free and overall survival in advanced biliary tract cancer
- (2015) J. Bridgewater et al. ANNALS OF ONCOLOGY
- Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial
- (2015) Alexander Stein et al. BMC CANCER
- Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
- (2015) A. Moeini et al. CLINICAL CANCER RESEARCH
- HER2/neu-directed therapy for biliary tract cancer
- (2015) Milind Javle et al. Journal of Hematology & Oncology
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatolithiasis and intrahepatic cholangiocarcinoma: A review
- (2015) Hyo Jung Kim WORLD JOURNAL OF GASTROENTEROLOGY
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
- (2014) Naveen S. Vasudev et al. ANGIOGENESIS
- Second-line chemotherapy in advanced biliary cancer: a systematic review
- (2014) A. Lamarca et al. ANNALS OF ONCOLOGY
- Hepatocellular carcinoma epidemiology
- (2014) Cristina Bosetti et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer
- (2014) Atsushi Aruga et al. Journal of Translational Medicine
- Liver transplantation for malignancy: Current treatment strategies and future perspectives
- (2014) Christina Hackl WORLD JOURNAL OF GASTROENTEROLOGY
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case–control analysis
- (2013) Giovanni Brandi et al. CANCER CAUSES & CONTROL
- Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis
- (2013) Kirsten Boonstra et al. HEPATOLOGY
- Intrahepatic Cholangiocarcinoma: Management Options and Emerging Therapies
- (2013) Rebecca M. Dodson et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- The role of the hepatitis viruses in cholangiocarcinoma
- (2013) S. Ralphs et al. JOURNAL OF VIRAL HEPATITIS
- BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma
- (2013) Benjamin Goeppert et al. MODERN PATHOLOGY
- Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
- (2013) D Sia et al. ONCOGENE
- Activation of Notch Signaling Is Required for Cholangiocarcinoma Progression and Is Enhanced by Inactivation of p53 In Vivo
- (2013) Mona El Khatib et al. PLoS One
- Right Portal Vein Ligation Combined With In Situ Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling 2-Staged Extended Right Hepatic Resection in Small-for-Size Settings
- (2012) Andreas A. Schnitzbauer et al. ANNALS OF SURGERY
- Evolution of Surgical Treatment for Perihilar Cholangiocarcinoma
- (2012) Masato Nagino et al. ANNALS OF SURGERY
- Gallstones and cholecystectomy in relation to risk of intra- and extrahepatic cholangiocarcinoma
- (2012) H Nordenstedt et al. BRITISH JOURNAL OF CANCER
- Efficacy of Neoadjuvant Chemoradiation, Followed by Liver Transplantation, for Perihilar Cholangiocarcinoma at 12 US Centers
- (2012) Sarwa Darwish Murad et al. GASTROENTEROLOGY
- Risk factors for intrahepatic cholangiocarcinoma: Association between metformin use and reduced cancer risk
- (2012) Roongruedee Chaiteerakij et al. HEPATOLOGY
- Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma
- (2012) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
- (2012) Anne M. Horgan et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of BRAF V600 mutation in melanoma
- (2012) Paolo A Ascierto et al. Journal of Translational Medicine
- Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-medicare database
- (2011) Tania M. Welzel et al. HEPATOLOGY
- Risk factors for cholangiocarcinoma
- (2011) Gia L. Tyson et al. HEPATOLOGY
- Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma
- (2011) Koichi Shimizu et al. Journal of Hepato-Biliary-Pancreatic Sciences
- Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
- (2011) Jeeyun Lee et al. LANCET ONCOLOGY
- Prognostic Factors After Surgical Resection for Intrahepatic, Hilar, and Distal Cholangiocarcinoma
- (2010) Yoshiaki Murakami et al. ANNALS OF SURGICAL ONCOLOGY
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
- (2010) T Okusaka et al. BRITISH JOURNAL OF CANCER
- Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer
- (2010) Miho Kaida et al. JOURNAL OF IMMUNOTHERAPY
- Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci
- (2010) Espen Melum et al. NATURE GENETICS
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epidemiology of cholangiocarcinoma: An update focusing on risk factors
- (2009) Hai-Rim Shin et al. CANCER SCIENCE
- Notch signaling controls liver development by regulating biliary differentiation
- (2009) Y. Zong et al. DEVELOPMENT
- Extended bile duct resection liver and transplantation in patients with hilar cholangiocarcinoma: Long-term results
- (2009) Daniel Seehofer et al. LIVER TRANSPLANTATION
- RarePIK3CA hotspot mutations in carcinomas of the biliary tract
- (2008) Marc-Oliver Riener et al. GENES CHROMOSOMES & CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started